For example, bispecific antibodies have been designed to target tumor-specific antigens and the NKp46 activating receptor on NK cells (Innate Pharma).36 The Fc portion of tumor-specific antibodies bind CD16, a type III Fcγ receptor on NK cells that can activate antibody-dependent cell-mediated cytotoxicity against tumor cells. Here, NCR1 is linked to neoplasm.